189816-05-5

Basic information

• Product Name: 4-Chloro-7-methoxy-2-phenylquinoline
• Synonyms: 4-Chloro-7-methoxy-2-phenylquinoline
• CAS NO: 189816-05-5
• Molecular Formula: C₁₆H₁₂ClNO
• Molecular Weight: 269.73
• Mol File: 189816-05-5.mol
• Article Data: 9

Chemical Properties

• Melting Point: 96-99°C
• Boiling Point: 414.285 °C at 760 mmHg
• Flash Point: 204.353 °C
• Appearance: liquid
• Density: 1.237
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.638
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 3.46±0.27(Predicted)
• CAS DataBase Reference: 4-Chloro-7-methoxy-2-phenylquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro-7-methoxy-2-phenylquinoline(189816-05-5)
• EPA Substance Registry System: 4-Chloro-7-methoxy-2-phenylquinoline(189816-05-5)

Safety Data

• Hazardous Substances Data: 189816-05-5(Hazardous Substances Data)

Usage

General Description

4-Chloro-7-methoxy-2-phenylquinoline is a chemical compound with the molecular formula C16H11ClNO. It is a member of the quinoline family and contains a chlorine and a methoxy group attached to the quinoline ring, as well as a phenyl group. 4-Chloro-7-methoxy-2-phenylquinoline has potential applications in pharmaceuticals and medicinal chemistry due to its structural features and potential biological activities. The presence of the chloro and methoxy groups may influence the compound's pharmacokinetic and pharmacodynamic properties. Further research is necessary to explore the potential uses and properties of 4-Chloro-7-methoxy-2-phenylquinoline in the development of new drugs and therapeutic agents.

InChI:InChI=1/C16H12ClNO/c1-19-12-7-8-13-14(17)10-15(18-16(13)9-12)11-5-3-2-4-6-11/h2-10H,1H3

Upstream product

• 80819-63-2 N-(3-methoxy-phenyl)-benzimidoyl chloride 
• 5877-59-8 N-benzylidene-m-anisidine 
• 20430-72-2 7-methoxy-2-phenylquinolin-4-ol 
• 873970-07-1 4-hydroxy-7-methoxy-2-phenyl-quinoline-3-carboxylic acid ethyl ester 
• 873383-40-5 4-hydroxy-7-methoxy-2-phenyl-quinoline-3-carboxylic acid 
• 94-02-0 ethyl 3-oxo-3-phenylpropionate 
• 3446-58-0 3-oxo-3-phenylpropanamide 

Downstream Products

• 47632-17-7 N⁴,N⁴-diethyl-N¹-(7-methoxy-2-phenyl-[4]quinolyl)-1-methyl-butanediyldiamine 
• 21255-17-4 7-methoxy-2-phenylquinoline 
• 928162-13-4 (S)-tert-butoxycarbonylamino[4-(7-methoxy-2-phenylquinolin-4-yloxy)phenyl]acetic acid 
• 928162-18-9 C₃₇H₃₉N₃O₇ 
• 928162-19-0 C₃₄H₃₅F₂N₃O₇ 
• 928162-20-3 C₄₂H₄₈N₄O₈ 
• 928162-21-4 C₄₀H₄₆F₂N₄O₈ 
• 928162-25-8 C₄₀H₄₂N₄O₈S 
• 928162-26-9 C₃₉H₃₈N₄O₈S 
• 928162-27-0 C₃₈H₄₀N₄O₈S 
• 928162-28-1 C₄₁H₄₀N₄O₈S 
• 928162-29-2 C₃₆H₃₈F₂N₄O₈S 

Relevant articles and documents

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors

A novel series of P3-truncated macrocyclic HCV NS3/4A protease inhibitors containing a P2 proline-urea or carbamate scaffold was synthesized. Very potent inhibitors were obtained through the optimization of the macrocycle size, urea and proline substitution, and bioisosteric replacement of the P1 carboxylic acid moiety. Variation of the lipophilicity by introduction of small lipophilic substituents resulted in improved PK profiles, ultimately leading to compound 13Bh, an extremely potent (Ki = 0.1 nM, EC50 = 4.5 nM) and selective (CC50 (Huh-7 cells) > 50 μM) inhibitor, displaying an excellent PK profile in rats characterized by an oral bioavailability of 54% and a high liver exposure after oral administration.

Substituted cycloalkyl P1' hepatitis C virus inhibitors

The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.